Andere Sprachen Centogene N.V.

Aktien

A2PUCU

NL0014040206

CNTG

Verzögert Nasdaq Andere Börsenplätze 17:46:51 08.05.2024			% 5 Tage	% 1. Jan.
0,4 ^USD	-11,11 %		-9,09 %	-66,67 %

19.03.	Centogene und Takeda Pharmaceutical arbeiten bei der Diagnostik von lysosomalen Speicherkrankheiten zusammen	MT
19.03.	Centogene N.V. kündigt die Verlängerung einer laufenden Partnerschaft mit Takeda an, um Patienten mit lysosomalen Speicherkrankheiten weiterhin Zugang zu genetischen Tests zu gewähren	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Centogene N : Form 6-K	02.05.
Centogene Gets Nasdaq Noncompliance Notice	02.04.
CENTOGENE Receives Nasdaq Non-Compliance Notice	02.04.
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics	19.03.
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders	19.03.
Centogene N.V. Announces the Extension of an Ongoing Partnership with Takeda to Continue Providing Access to Genetic Testing for Patients with Lysosomal Storage Disorders	19.03.
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency	29.02.
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing	28.02.
CENTOGENE Explores Strategic Alternatives	28.02.
Centogene Explores Strategic Alternatives	28.02.
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration	25.01.
Centogene N.V. and the Laboratory of Human Genetics of Infectious Diseases At Institut Imagine Announce Rare Disease Research Collaboration	25.01.
CENTOGENE Receives French Research Tax Credit Accreditation	24.01.
Centogene N.V. and The Michael J. Fox Foundation for Parkinson's Research Announces Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics	23.01.
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics	23.01.
CENTOGENE Announces Preliminary Full Year 2023 Revenue	18.01.
Centogene N.V. Provides Earnings Guidance for the Full Year 2023	18.01.
Centogene N : Minutes for Centogene EGM December 2023	19.12.
CENTOGENE Announces Voting Results of Extraordinary General Meeting	19.12.
Centogene N.V. Announces Changes to Supervisory Board	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Centogene N.V.

Aktien

A2PUCU

NL0014040206

CNTG

Andere Sprachen

Filter